Quantinno Capital Management LP Acquires 322 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Quantinno Capital Management LP boosted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 32.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,308 shares of the biotechnology company’s stock after purchasing an additional 322 shares during the period. Quantinno Capital Management LP’s holdings in United Therapeutics were worth $469,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Meiji Yasuda Asset Management Co Ltd. lifted its position in shares of United Therapeutics by 1.6% during the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company’s stock worth $652,000 after buying an additional 33 shares during the period. Toronto Dominion Bank lifted its holdings in shares of United Therapeutics by 0.8% during the second quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company’s stock valued at $1,441,000 after acquiring an additional 37 shares during the period. ClariVest Asset Management LLC boosted its stake in shares of United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 42 shares in the last quarter. Benjamin F. Edwards & Company Inc. grew its holdings in shares of United Therapeutics by 14.0% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 42 shares during the last quarter. Finally, First Citizens Bank & Trust Co. increased its position in shares of United Therapeutics by 1.8% during the 3rd quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company’s stock worth $961,000 after purchasing an additional 48 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have commented on UTHR shares. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Argus increased their price target on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. HC Wainwright lifted their price objective on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Oppenheimer increased their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Finally, Jefferies Financial Group lifted their price target on United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a report on Monday, September 23rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $370.86.

Insider Activity

In related news, Director Christopher Causey sold 510 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $376.63, for a total transaction of $192,081.30. Following the sale, the director now owns 3,675 shares of the company’s stock, valued at approximately $1,384,115.25. This trade represents a 12.19 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Paul A. Mahon sold 7,700 shares of the business’s stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $374.37, for a total value of $2,882,649.00. Following the completion of the transaction, the executive vice president now directly owns 36,710 shares of the company’s stock, valued at approximately $13,743,122.70. The trade was a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 119,340 shares of company stock valued at $44,765,530 in the last ninety days. 11.90% of the stock is owned by insiders.

United Therapeutics Stock Performance

UTHR opened at $361.81 on Friday. The company has a fifty day moving average price of $369.94 and a two-hundred day moving average price of $342.19. The firm has a market capitalization of $16.15 billion, a PE ratio of 15.89, a P/E/G ratio of 1.05 and a beta of 0.54. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. During the same period in the previous year, the firm earned $5.38 earnings per share. The firm’s quarterly revenue was up 22.9% compared to the same quarter last year. Equities analysts forecast that United Therapeutics Co. will post 25.22 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.